MRNS - Rasio kapitalisasi pasar marang pendapatan Marinus
Marinus Pharmaceuticals attracts scientists with its ethical culture and focus on helping epilepsy patients. After analyzing the price-to-sales ratio dynamics on GURU.Markets, we find that 1.00 expresses the current value of this metric. Orphan drug status grants the company exceptional pricing power, although final revenue depends on insurance fund limits and patent protection.
Rincian metrik lan analitis perusahaan Marinus Pharmaceuticals (MRNS)
- rega lan prakiraan konsensus rega:
- statistik kapitalisasi pasar:
- indikator kapitalisasi buku:
- indikator beban kredit lan likuiditas emiten:
Total Utang marang Modal Marinus Pharmaceuticals|MRNS - Utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal marinuspharma.com|MRNS - Utang perusahaan|Utang marang nilai buku Marinus Pharma|MRNS - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Marinus Pharmaceuticals|Indikator likuiditas cepet marinuspharma.com
- indikator bathi lan kelipatan valuasi:
MRNS - Bathi resik|Bathi resik sing dikarepake Marinus Pharmaceuticals|MRNS - Koefisien rega marang bathi|Pangali Forward P/E Marinus Pharmaceuticals|MRNS - Pangali rega marang bathi tumrap wutah|Koefisien nilai perusahaan marang bathi operasional sadurunge panyusutan Marinus Pharma|MRNS - Bathi operasional EBITDA|Bathi resik saben saham sajrone patang kuartal pungkasan Marinus Pharmaceuticals|MRNS - Bathi resik saben saham (EPS TTM)|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan marinuspharma.com|MRNS - Wutah bathi ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Marinus Pharmaceuticals
- rincian pendapatan lan dodolan emiten:
Analisis fundamental perusahaan:MRNS (Marinus Pharmaceuticals, Inc.)
This multiple is calculated as the ratio of market capitalization to total annual revenue, determining the value per unit of revenue within the asset's valuation structure. Amid cost reductions aimed at preserving the pipeline of Marinus Pharmaceuticals (MRNS), the P/S ratio allows for an assessment of whether the business is undervalued or if there is a risk of overpayment against the backdrop of management restructuring following failed clinical trials.
Perusahaan pesaing
BIIB (Biogen) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S NBIX (Neurocrine Corp)|Regencell Bioscience - Rasio rega marang pendapatan|Axsome Therapeutics - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan ACAD (ACADIA Pharmaceuticals)|Xenon (XENE) - Rasio rega marang pendapatan|Rega marang dodolan Viking Therapeutics Inc (VKTX)|SUPN (Supernus Pharma) - Multiplikator P/S|CPRX: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S DNLI|Koefisien rega marang pendapatan Harmony Biosciences|Biohaven Ltd - Kapitalisasi marang pendapatan|Multiplikator P/S Amylyx Pharmaceuticals, Inc. AMLX|TRVI: Kapitalisasi marang pendapatan|Koefisien rega marang pendapatan Praxis Corp PRAX|AVXL: Multiplikator P/S|CBLL (ceribell.com) - Rasio rega marang pendapatan|PRTA (Prothena Corporation) - Multiplikator P/S|Kapitalisasi marang pendapatan alector.com (ALEC)|Rasio rega marang pendapatan Annexon, Inc. (ANNX)|OMER - Rega marang dodolan|Multiplikator P/S NGNE (Neurogene Inc)|AC Immune (ACIU) - Rega marang dodolan|Voyager Therapeutics Inc - Multiplikator P/S|Neumora (NMRA) - Kapitalisasi marang pendapatan|SCLX: Multiplikator P/S|TVGN - Koefisien rega marang pendapatan|ACOG (Alpha Cognition Inc) - Multiplikator P/S|Kapitalisasi marang pendapatan cogrx.com (CGTX)|Rasio rega marang pendapatan Inhibikase Therapeutics Inc (IKT)|Koefisien rega marang pendapatan Cassava Sciences|Multiplikator P/S ASRT (Assertio Holdings)|COYA - Kapitalisasi marang pendapatan|vistagen.com - Multiplikator P/S|OVID: Rasio rega marang pendapatan|Acumen Pharmaceuticals, Inc (ABOS) - Rasio rega marang pendapatan|CervoMed Inc - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Alterity Therapeutics Limited|clene.com (CLNN) - Koefisien rega marang pendapatan|Kapitalisasi marang pendapatan PEPG (PepGen Inc)|Multiplikator P/S jupiterneurosciences.com (JUNS)|Rasio rega marang pendapatan Relmada Therapeutics, Inc. RLMD|ANVS: Rasio kapitalisasi marang pendapatan|Grace Tx - Multiplikator P/S|AIFF (Firefly Neuroscience Inc) - Rasio kapitalisasi marang pendapatan|KLTO: Multiplikator P/S|NeuroSense Therapeutics, Ltd. (NRSN) - Multiplikator P/S|Rasio rega marang pendapatan Reviva Pharmaceuticals, Inc.|Kapitalisasi marang pendapatan metaviatx.com (MTVA)|Multiplikator P/S NRXS|HSDT - Rega marang dodolan|Passage Bio, Inc. - Kapitalisasi marang pendapatan|bionomics.com.au (NEUP) - Rega marang dodolan|Minerva - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan ATHA (Athira Pharma Inc)|ADXN: Multiplikator P/S|Rasio kapitalisasi marang pendapatan ALZN|CYCN (Cyclerion Therapeutics Inc.) - Multiplikator P/S|PTIX (Protagenic Therapeutics) - Kapitalisasi marang volume dodolan|Multiplikator P/S KTTA|Koefisien rega marang pendapatan Cortigent|Multiplikator P/S ATXI (avenuetx.com)|BrainStorm Cell Therapeutics Inc. - Rasio rega marang pendapatan|Cara Therapeutics Inc. - Multiplikator P/S|Chromocell Therapeutics (CHRO) - Kapitalisasi marang pendapatan|ELYM: Multiplikator P/S|Kapitalisasi marang pendapatan Intra-Cellular Therapies Inc.|LBPH (Longboard Pharmaceuticals Inc) - Multiplikator P/S|NKGN: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S NRBO|SAGE: Rasio rega marang dodolan|Synaptogenix Inc. - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan TRVN (Trevena Inc.)|Vigil Neuroscience, Inc. - Multiplikator P/S|Anew Medical (WENA) - Kapitalisasi marang pendapatan|CERE (Cerevel Corp) - Kapitalisasi marang pendapatan
